Project Grant R01HL188006
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $719K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $127,168 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model the effect of apolipoprotein L1 risk variants on cardiovascular disease risk in African American e-cigarette users. The research employs human induced pluripotent stem-cell-derived endothelial cells to investigate how e-cigarettes, with and without menthol, affect endothelial health in...
- The National Heart Lung and Blood Institute awarded $827,439 to Lundquist Institute For Biomedical Innovation At Harbor-UCLA Medical Center on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms by which perinatal nicotine vaping exposure dysregulates pulmonary group 2 innate lymphoid cells (ILC2s) and promotes allergic asthma development in offspring. The research employs electronic nicotine delivery system (ENDS) exposure models and...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $821,294 to The Trustees of Columbia University in the City of New York on September 1, 2026, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077, Project Grant R01HL179303). The award funds the VAPESCAN study, a longitudinal investigation examining early lung toxicity associated with e-cigarette versus cigarette use in young adults aged 18–50....
- The National Heart Lung and Blood Institute awarded the University of Utah $470,606 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the molecular mechanisms of smoking-induced endothelial dysfunction associated with the ALDH2*2 genetic variant. The research employs a multidisciplinary approach integrating stem cell biology, molecular biology, toxicology, vascular physiology, and endothelial mechanobiology to understand how tobacco consumption...
- The National Heart, Lung, and Blood Institute awarded Vassar College $222,750 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to examine cross-sectional and longitudinal associations of smoking behavior with subclinical vascular brain injury and microvascular function. The award funds research leveraging the longitudinal, community-based Framingham Heart Study to investigate how cigarette smoking and cessation affect vascular brain injury and peripheral and...
- The National Heart, Lung, and Blood Institute awarded the University of California, Davis $770,045 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate tobacco smoke-driven fibroblast reprogramming in pulmonary fibrosis. The research deciphers molecular mechanisms by which tobacco smoke promotes fibrotic remodeling in the lungs. Using proteomic and metabolomic profiling, the investigator identified tobacco smoke–induced lactate accumulation and...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $234,000 on September 1, 2026, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077, Assistance Listing 93.077) to examine how the duration of electronic nicotine delivery systems (ENDS) use affects cardiopulmonary health outcomes among adults with current or former cigarette smoking histories. The research leverages prospective, nationally...
- The National Heart, Lung, and Blood Institute awarded the University of Maryland, Baltimore $116,625 under Project Grant R03HL188068 on August 15, 2026, to conduct a randomized, within-subject crossover study comparing cardiovascular effects of combustible cigarette smoking and electronic cigarette use in older adults with hypertension. The study enrolls 30 participants aged 50 and older with hypertension and assigns each to two 14-day phases: continued smoking and exclusive use of an authorized...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $1,541,206 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify druggable targets for cancer therapy-induced cardiotoxicity. The research characterizes proteasome inhibitor-induced cardiovascular toxicity through three aims. Aim 1 profiles cell type-specific cytotoxicity using patient-specific induced pluripotent stem cell-derived cardiomyocytes and endothelial...